Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia Gravis

In this economic evaluation, thymectomy was found to be a highly cost-effective intervention for nonthymomatous MG in the UK and likely to be cost-saving relative to prednisolone alone. These findings support current clinical guidelines recommending thymectomy for eligible patients and establish it as the most relevant comparator in evaluations of future health technologies. More broadly, this study demonstrates the importance of high-quality randomized clinical trial evidence in enabling health technology assessment of surgical procedures.